<DOC>
	<DOC>NCT01760265</DOC>
	<brief_summary>Dysbetalipoproteinemia (type III, Fredrickson's classification) is a rare metabolic disorder. It results from a defect in the clearance of VLDL and chylomicron remnants due to homozygous APOE2 variants or heterozygous APOE mutations, and there is an elevated plasma cholesterol and triglycerides. As a consequence of the derangements in lipoprotein metabolism, dysbetalipoproteinemia predispose to the premature development of atherosclerosis. However among this population there is heterogeneity in development of cardiovascular complications and the determinants remain unclear actually. The aim of the investigators study is to evaluate the intensity of clinical atherosclerosis, and identify its determinants.</brief_summary>
	<brief_title>DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk"</brief_title>
	<detailed_description />
	<mesh_term>Plaque, Atherosclerotic</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type III</mesh_term>
	<criteria>apo E gene sequencing in CBE (Centre de Biologie Est / Hospices Civils de Lyon / France) laboratory in Lyon until December 2012 age &lt; 40 years refused participation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>dysbetalipoproteinemia</keyword>
	<keyword>artery calcium score</keyword>
	<keyword>carotid intima media</keyword>
	<keyword>ankle brachial index</keyword>
	<keyword>dysbetalipoproteinemic patients</keyword>
</DOC>